iCell Gene Therapeutics Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
1
iCell Gene Therapeutics General Information
Description
Developer of gene therapeutics technology designed to target and destroy multiple types of cancer. The company's chimeric antigen receptor-engineered cells eradicate devastating diseases by entering the clinical study directed against T-cell malignancies by creating novel immunotherapies for cancer treatment, enabling patients with resistant cancer to get cost-effective cures.
Contact Information
Website
www.icellgene.comCorporate Office
- 25 Health Sciences Drive
- Suite 118, Stony Brook
- Brookhaven, NY 11790
- United States
Corporate Office
- 25 Health Sciences Drive
- Suite 118, Stony Brook
- Brookhaven, NY 11790
- United States
iCell Gene Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 |
iCell Gene Therapeutics Patents
iCell Gene Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4626926-A2 | Engineered immune cells for treating disorders, compositions and methods thereof | Pending | 28-Nov-2022 | ||
| US-20240350632-A1 | Engineered immune cells for treating disorders, compositions and methods thereof | Pending | 28-Nov-2022 | ||
| WO-2024118559-A2 | Engineered immune cells for treating disorders, compositions and methods thereof | Inactive | 28-Nov-2022 | ||
| WO-2024118559-A3 | Engineered immune cells for treating disorders, compositions and methods thereof | Inactive | 28-Nov-2022 | ||
| WO-2022076256-A1 | Engineered immune cells for immunotherapy using endoplasmic retention techniques | Inactive | 05-Oct-2020 | A61K40/4224 |
iCell Gene Therapeutics Signals
iCell Gene Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Long Island High Technology Incubator | Accelerator/Incubator |
iCell Gene Therapeutics FAQs
-
When was iCell Gene Therapeutics founded?
iCell Gene Therapeutics was founded in 2014.
-
Where is iCell Gene Therapeutics headquartered?
iCell Gene Therapeutics is headquartered in Brookhaven, NY.
-
What is the size of iCell Gene Therapeutics?
iCell Gene Therapeutics has 11 total employees.
-
What industry is iCell Gene Therapeutics in?
iCell Gene Therapeutics’s primary industry is Drug Discovery.
-
Is iCell Gene Therapeutics a private or public company?
iCell Gene Therapeutics is a Private company.
-
What is iCell Gene Therapeutics’s current revenue?
The current revenue for iCell Gene Therapeutics is .
-
Who are iCell Gene Therapeutics’s investors?
Long Island High Technology Incubator has invested in iCell Gene Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process